Premium
Fingolimod‐associated cystoid macular oedema
Author(s) -
LIU L,
CUTHBERTSON F
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2014.3414.x
Subject(s) - fingolimod , medicine , macular edema , incidence (geometry) , ophthalmology , dermatology , multiple sclerosis , visual acuity , immunology , physics , optics
Fingolimod‐associated cystoid macular oedema has been reported in treatment of MS and following renal transplantation. This seems to be dose‐dependent with an incidence of approximately 0.5% with 0.5mg oral dose. Although most patients develop macular oedema between 3 to 4 months after initiation, we reported an incidence as early as 5 days. The mechanism underlying fingolimod‐associated macular oedema is not entirely clear. It has been shown that fingolimod, the S1P receptor, not only plays a role in recruiting T lymphocytes, but also in regulating vascular permeability. Patients on fingolimod should be advised of the possible adverse visual symptoms. It may be helpful for patient to self‐monitor with an Amsler chart, and urgent ophthalmology review is suggested for patients with painless reduced vision.